The effect of Silymarin on dyslipidemic patients with Alzheimer's disease

Phase 3

Recruiting

• Conditions: Alzheimer's disease.; Alzheimer's disease with late onset; G30.1

• Registration Number: IRCT20210901052360N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

The patient has sporadic Alzheimer's disease.
The patient has a mild degree of Alzheimer's disease.
The patient has dyslipidemia.
Patients whose Alzheimer's disease has been confirmed by clinical evaluation or imaging techniques and biochemical tests by a neurologist.

Exclusion Criteria

The patient has no history of viral hepatitis.
The patient has not had alcohol misuse, smoking or drug abuse in the last month.
The patient should not take chemotherapy drugs.
The patient does not have active rheumatic disorders.
The patient does not have diabetes and uncontrolled hypertension.
The patient has no history of brain surgery.
The patient does not have advanced heart failure, acute cardiovascular disease, or chronic renal failure.
The patient does not have hypothyroidism.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
-acetyl-aspartate (NAA) metabolite. Timepoint: Before and after the intervention (6 months). Method of measurement: Part per million (ppm) in MR spectroscopy and percentage.;Amyloid beta-42 (Aß42). Timepoint: Before and after the intervention (6 months). Method of measurement: ELISA kit.